Ani Pharmaceuticals (ANIP) Receivables (2012 - 2026)

Ani Pharmaceuticals has disclosed Receivables across 15 years of filings, most recently posting $255.4 million for Q1 2026.

• Receivables for Q1 2026 came in at $255.4 million, up 15.93% year-over-year; the trailing twelve-month figure through Mar 2026 was $255.4 million (up 15.93% YoY), and the FY2025 annual result was $281.1 million, up 26.77% from the prior year.
• Receivables came in at $255.4 million for Q1 2026 at Ani Pharmaceuticals, down from $281.1 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $281.1 million in Q4 2025 to a low of $131.6 million in Q1 2022.
• The 5-year median for Receivables is $174.7 million (2023), against an average of $192.5 million.
• Across the five-year window, Receivables soared 62.35% in 2022 and decreased 4.9% in 2023, its largest moves.
• Ani Pharmaceuticals' Receivables stood at $170.4 million in 2022, then declined by 4.9% to $162.1 million in 2023, then surged by 36.8% to $221.7 million in 2024, then gained by 26.77% to $281.1 million in 2025, then retreated by 9.13% to $255.4 million in 2026.
• The last three Receivables figures came in at $255.4 million (Q1 2026), $281.1 million (Q4 2025), and $252.6 million (Q3 2025), per Business Quant data.